The first reported trial of a BRAF inhibitor (sorafenib) for pediatric gliomas did not report any secondary skin cancer formation, but instead reported a significant stimulation of glioma tumor growth, which we did not observe in our cohort [16]. This evidence concerns the gene BRAF and skin neoplasm.